MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41591-023-02469-3

Медицинская библиотека · Nature medicine · 2023

Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.

Yin Jun, Yuan Jingnan, Li Yunjin, Fang Yong, Wang Ruoxi, Jiao Heng, Tang Han, Zhang Shaoyuan, Lin Siyun, Su Feng, Gu Jianmin, Jiang Tian, Lin Dong, Huang Zhiliang, Du Chaoxiang, Wu Kui, Tan Lijie, Zhou Qing

Клиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Overall survival (OS) benefits of neoadjuvant immunotherapy remain elusive in locally advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of a phase 1b trial of neoadjuvant PD-L1 blockade with adebrelimab in resectable ESCC. Patients received two neoadjuvant doses of adebrelimab followed by surgery. The primary endpoints were safety and feasibility; secondary endpoints included pathologic complete response (pCR) and OS. Our data showed the primary endpoints of safety and feasibility had been met. Common treatment-related adverse events were anorexia (32%) and fatigue (16%), without grade 3 or more adverse events. Of the 30 patients enrolled in the trial, 25 underwent successful resection without surgery delay and 24% had major pathologic responses including a pCR rate of 8%. The 2-year OS was 92%. Responsive patients had an immune-enriched tumor microenvironment phenotype, whereas nonresponsive patients had greater infiltration of cancer-associated fibroblasts at baseline. Clonotypic dynamics of pre-existing intratumoral T cells was a hallmark of responsive patients. These findings provide a rational for neoadjuvant anti-PD-L1 monotherapy as a therapeutic strategy for patients with resectable ESCC. ClinicalTrials.gov identifier: NCT04215471 .

Для цитирования: Yin Jun, Yuan Jingnan, Li Yunjin, Fang Yong, Wang Ruoxi, Jiao Heng, Tang Han, Zhang Shaoyuan, Lin Siyun, Su Feng, Gu Jianmin, Jiang Tian, Lin Dong, Huang Zhiliang, Du Chaoxiang, Wu Kui, Tan Lijie, Zhou Qing. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.. Nature medicine. 2023. DOI: 10.1038/s41591-023-02469-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.